Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
Cancer immunotherapy is seeing an increasing focus on vaccination with tumor-associated antigens (TAAs). Human telomerase (hTERT) is a TAA expressed by most tumors to overcome telomere shortening. Tolerance to hTERT can be easily broken both naturally and experimentally and hTERT DNA vaccine candidates have been introduced in clinical trials. DNA prime/boost strategies have been widely developed to immunize efficiently against infectious diseases. We explored the use of a recombinant measles virus (MV) hTERT vector to boost DNA priming as recombinant live attenuated measles virus has an impressive safety and efficacy record. Here, we show that a MV-TERT vector can rapidly and strongly boost DNA hTERT priming in MV susceptible IFNAR/CD46 mouse models. The cellular immune responses were Th1 polarized. No humoral responses were elicited. The 4 kb hTERT transgene did not impact MV replication or induction of cell-mediated responses. These findings validate the MV-TERT vector to boost cell-mediated responses following DNA priming in humans.
KeywordsCancer Immunotherapy hTERT Measles virus vaccine T-cell responses
Additional transcription unit
Cytometric beads array
Multiplicity of infection
Nitro blue tetrazolium chloride
Region of interest
Universal cancer peptide
The authors would like to thank Ludovic Bourré, Anne-Sophie Pailhes-Jimenez, Emanuèle Bourges, Rahima Youssi and Pascal Clayette for experimental and editorial help, and the staff of the Institut Pasteur’s animal facilities and imaging platform. Funding was provided by Association Nationale de la Recherche et de la Technologie (Grant no. 2012/0152).
SW-H, FT and PL-D conceived the project. They also shared their knowledge and experience to help EP with the experimental program design. EP performed and analyzed the experiments under the supervision of CL and TH. EP and CR carried out mice experiments. VN and CC constructed the recombinant measles telomerase virus. ME, JT, TB and MJ provided technical help. EP analysed all the data and wrote the manuscript together with SW-H and FT. All authors viewed and approved the final version of the manuscript.
We would like to thank Shannon A. Fairbanks and Bernardo Fort Brescia for their unswerving support. Elodie Pliquet was supported by an industrial Ph.D. fellowship from the French National Association of Research and Technology (ANRT).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval and ethical standards
All protocols have been submitted and approved by the Pasteur Institute office of laboratory animal care CETEA no. 89 under the references 2013-0026 on February 01st, 2013 and 2014-0061 on October 07th, 2015 and by French Committee for Hygiene, Safety and Working Conditions (CHSCT) under the reference 07.157 on April 10th, 2007 and 16.0013 on January 8th, 2016. All in vivo experiments were conducted in strict accordance with good animal practice and complied with local animal experimentation and ethics committee guidelines of the Pasteur Institute (agreement no. 75-15-01 delivered on the 06th September 2013 and no. A75-15-01-1 on 18th August 2014) and Directive 2010/63/EU on the harmonization of laws, regulations and administrative provisions relating to the protection of animals.
IFNAR/CD46 (IFN-α/βR−/− CD46+/−) mouse strain used for immunization experiments was generated by Frédéric Tangy’s team by cross-breeding and backcross between FVB/CD46+/− mice (gift from F. Grosveld, Erasmus University, Rotterdam, The Netherlands) and 129sv IFN-α/βR−/− mice which lack the type I IFN receptor (gift from M. Aguet, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland). HHD/IFNAR/CD46 (HHD+/+ CD46+/− IFN-α/βR−/−) mouse strain was generated by Frédéric Tangy’s team by cross-breeding and backcross between HHD mice (human β2m–HLA-A2.1 α1α2-H-2Dbα3-transmembrane and H-2Db−/−β2mb−/− double knockout; mice generated at Pasteur Institute by François Lemonnier) and IFNAR/CD46 mice.
Cell line authentication
HEK-293-T7-MV cell line was produced, provided and patented by Frédéric Tangy and the Institut Pasteur. Vero cells were provided by the American Type Culture Collection (ATCC®) under reference number CCL-81™.
- 12.Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, Despres P, Tauber E, Jilma B, Tangy F (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15(5):519–527. https://doi.org/10.1016/S1473-3099(15)70043-5 CrossRefGoogle Scholar
- 14.Russell SJ, Peng KW (2009) Measles virus for cancer therapy. Curr Top Microbiol Immunol 330:213–241Google Scholar
- 23.Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M, Kostrzak A, Pailhes-Jimenez A-S, Bourges E, Loustau M, Caumartin J, Lachgar A, Huet T, Wain-Hobson S, Langlade-Demoyen P (2016) Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology 5(3):e1083670. https://doi.org/10.1080/2162402X.2015.1083670 CrossRefGoogle Scholar
- 26.Hallengärd D, Lum F-M, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LFP, Esteban M, Liljeström P (2014) Prime-boost immunization strategies against chikungunya virus. J Virol 88(22):13333–13343. https://doi.org/10.1128/JVI.01926-14 CrossRefGoogle Scholar
- 27.Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113(2):259–266. https://doi.org/10.1002/ijc.20569 CrossRefGoogle Scholar
- 34.Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77(21):11546–11554. https://doi.org/10.1128/JVI.77.21.11546-11554.2003 CrossRefGoogle Scholar
- 35.Lorin C, Delebecque F, Labrousse V, Da Silva L, Lemonnier F, Brahic M, Tangy F (2005) A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23(36):4463–4472. https://doi.org/10.1016/j.vaccine.2005.04.024 CrossRefGoogle Scholar
- 36.Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185(12):2043–2051. https://doi.org/10.1084/jem.185.12.2043 CrossRefGoogle Scholar
- 37.Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99(19):12275–12280. https://doi.org/10.1073/pnas.182418399 CrossRefGoogle Scholar
- 38.Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotevi O (2012) Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res Off J Am Assoc Cancer Res 18(22):6284–6295. https://doi.org/10.1158/1078-0432.CCR-12-0896 CrossRefGoogle Scholar
- 39.Komarova AV, Combredet C, Meyniel-Schicklin L, Chapelle M, Caignard G, Camadro JM, Lotteau V, Vidalain PO, Tangy F (2011) Proteomic analysis of virus–host interactions in an infectious context using recombinant viruses. Mol Cell Proteom 10(12):M110 007443. https://doi.org/10.1074/mcp.M110.007443 CrossRefGoogle Scholar
- 44.Tasaki T, Sriram SM, Park KS, Kwon YT (2012) The N-end rule pathway. Annu Rev Biochem 81:261–289. https://doi.org/10.1146/annurev-biochem-051710-093308 CrossRefGoogle Scholar
- 45.Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R (1998) Measles virus spread and pathogenesis in genetically modified mice. J Virol 72(9):7420–7427Google Scholar
- 46.Ludlow M, de Vries RD, Lemon K, McQuaid S, Millar E, van Amerongen G, Yuksel S, Verburgh RJ, Osterhaus AD, de Swart RL, Duprex WP (2013) Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus. J Gen Virol 94(Pt 9):1933–1944. https://doi.org/10.1099/vir.0.054650-0 CrossRefGoogle Scholar